Anna Maria Matilda Quigley

Title: Anna Maria Matilda Quigley: Innovator in Antibody Research

Introduction

Anna Maria Matilda Quigley is a prominent inventor based in Macquarie Park, Australia. She has made significant contributions to the field of antibody research, particularly in the development of innovative therapies targeting human PAR-2. With a total of 2 patents to her name, Quigley's work has the potential to impact various medical conditions.

Latest Patents

Quigley's latest patents focus on Anti-PAR-2 antibodies and methods of use thereof. The disclosures provide antibodies and antigen-binding fragments that specifically bind to human PAR-2. These antibodies block the interaction between a PAR-2 activating ligand and the extracellular domain of PAR-2, effectively inhibiting PAR-2 activation. This innovation holds promise for treating diseases associated with increased expression of PAR-2, including airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain related to various diseases.

Career Highlights

Quigley is currently associated with Cephalon, Inc., where she continues her research and development efforts. Her work is characterized by a commitment to advancing therapeutic options through innovative antibody technologies.

Collaborations

Some of her notable coworkers include Anna Mikaela Bracken and Adam Clarke, who contribute to the collaborative environment that fosters innovation at Cephalon, Inc.

Conclusion

Anna Maria Matilda Quigley is a trailblazer in the field of antibody research, with her innovative patents paving the way for new treatments for various medical conditions. Her contributions are invaluable to the scientific community and hold great promise for future advancements in healthcare.